Clinical Trial Update: Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes [Phase 3]

View source ↗

Summary

Phase 3 trial of amifampridine phosphate for congenital myasthenic syndromes has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Myasthenic Syndromes

Drugs mentioned

• Amifampridine phosphate (amifampridine phosphate)

Snippet

Sponsor: Catalyst Pharmaceuticals, Inc. | Conditions: Myasthenic Syndromes, Congenital | Phase 3 | Status: COMPLETED | Results posted: 2021-04-02